8-K Announcements
6Material company update
Mar 24, 2026·SEC
Material company update
Nov 6, 2025·SEC
Material company update
Oct 7, 2025·SEC
Achieve Life Sciences, Inc.(ACHV)Earnings, Financials & Key Ratios
ACHV•NASDAQ
$4.80
$253M mkt cap·Price updated May 6, 2026
AboutAchieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.Show more
- Revenue$0
- EBITDA$0+100.0%
- Net Income-$55M-37.2%
- EPS (Diluted)-1.25-0.8%
- ROE-257.67%+37.1%
- Debt/Equity0.70+45.9%
ACHV Key Insights
Achieve Life Sciences, Inc. (ACHV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 35.9% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ACHV Price & Volume
Achieve Life Sciences, Inc. (ACHV) stock price & volume — 10-year historical chart
Loading chart...
ACHV Growth Metrics
Achieve Life Sciences, Inc. (ACHV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-58.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-22.12%
Return on Capital
10 Years-185.17%
5 Years-320.97%
3 Years-521.28%
Last Year-
ACHV Recent Earnings
Achieve Life Sciences, Inc. (ACHV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)
Q2 2026Latest
Mar 24, 2026EPS
$0.28
Est $0.27
-3.7%
Revenue
—
Q4 2025
Nov 6, 2025EPS
$0.28
Est $0.24
-16.7%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.37
Est $0.37
+0.0%
Revenue
—
Q2 2025
May 13, 2025EPS
$0.37
Est $0.37
+0.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 24, 2026 | $0.28vs $0.27-3.7% | — |
| Q4 2025 | Nov 6, 2025 | $0.28vs $0.24-16.7% | — |
| Q3 2025 | Aug 7, 2025 | $0.37vs $0.37+0.0% | — |
| Q2 2025 | May 13, 2025 | $0.37vs $0.37+0.0% | — |
Based on last 12 quarters of dataView full earnings history →
ACHV Peer Comparison
Achieve Life Sciences, Inc. (ACHV) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PTGX | 6.63B | 103.97 | -50.72 | -89.41% | -6.48% | -17.76% | 0.02 | |
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 | |
 GFAI | 10.88M | 0.50 | -0.94 | 0.18% | -32.94% | -69.69% | 0.08 | |
 OWLT | 2.92B | 5.20 | -2.32 | 35.42% | -36.32% | -5.88% | 0.37 | |
 CHRS | 212.02M | 1.75 | 1.22 | -84.2% | 398.43% | 7.89% | 0.02 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 CLOV | 1.37B | 2.68 | -15.76 | 40.34% | -2.58% | -17.08% | ||
 MNKD | 1.1B | 3.56 | 178 | 22.23% | -6.63% |
Compare ACHV vs Peers
Achieve Life Sciences, Inc. (ACHV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACHV Income Statement
Achieve Life Sciences, Inc. (ACHV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -100% | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 282K | 282K | 254K | 255K | 0 | 0 | 0 | 229K | 0 | 54K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -282K▲ 0% | -282K▲ 0.0% | -254K▲ 9.9% | -255K▼ 0.4% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -229K▲ 0% | 0▲ 100.0% | -54K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -105.57% | 0% | 9.93% | -0.39% | 100% | - | - | - | 100% | - |
| Operating Expenses | 6.63M | 12.81M | 16.53M | 14.49M | 33.09M | 40.8M | 27.25M | 38.84M | 54.88M | 52.34M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.53M | 6.95M | 6.85M | 7.61M | 9.13M | 10.72M | 11.44M | 16.25M | 31.87M | 25.92M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 3.1M | 5.87M | 9.67M | 6.88M | 23.97M | 30.08M | 15.81M | 22.82M | 22.96M | 26.42M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 165K | 126K | 133K | 0 | 0 | 0 | 0 | -229K | 48K | 0 |
| Operating Income | -6.63M▲ 0% | -12.81M▼ 93.2% | -16.53M▼ 29.0% | -14.75M▲ 10.8% | -33.09M▼ 124.4% | -40.8M▼ 23.3% | -27.25M▲ 33.2% | -39.07M▼ 43.4% | 0▲ 100.0% | -52.34M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 68.71% | -93.2% | -28.99% | 10.76% | -124.37% | -23.29% | 33.21% | -43.37% | 100% | - |
| EBITDA | -6.35M | -12.53M | -16.27M | -14.49M | -32.84M | -40.56M | -27.02M | -38.84M | 0 | -52.11M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 69.77% | -97.34% | -29.87% | 10.93% | -126.59% | -23.51% | 33.38% | -43.73% | 100% | -67.89% |
| D&A (Non-Cash Add-back) | 282K | 282K | 254K | 255K | 250K | 236K | 228K | 229K | 0 | 230K |
| EBIT | -13.63M | -12.69M | -16.39M | -14.73M | -33.15M | -40.56M | -26.96M | -37.65M | 0 | -51.58M |
| Net Interest Income | 0 | 0 | 170K | 69K | 17K | -1.59M | -2.03M | 176K | 0 | 785K |
| Interest Income | 21K | 171K | 170K | 69K | 17K | 199K | 825K | 2.36M | 1.5M | 1.55M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 1.79M | 2.85M | 2.18M | -819K | 765K |
| Other Income/Expense | -7M | 126K | 133K | 20K | -58K | -1.55M | -2.56M | -758K | 0 | -7K |
| Pretax Income | -13.63M▲ 0% | -12.69M▲ 6.9% | -16.39M▼ 29.2% | -14.73M▲ 10.2% | -33.15M▼ 125.1% | -42.35M▼ 27.7% | -29.82M▲ 29.6% | -39.83M▼ 33.6% | -54.65M▼ 37.2% | -52.35M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | -3.05M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 22.38% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -10.58M▲ 0% | -12.69M▼ 19.9% | -16.39M▼ 29.2% | -14.66M▲ 10.6% | -33.15M▼ 126.1% | -42.35M▼ 27.7% | -29.82M▲ 29.6% | -39.83M▼ 33.6% | -54.65M▼ 37.2% | -52.35M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 47.42% | -19.88% | -29.23% | 10.58% | -126.12% | -27.74% | 29.6% | -33.58% | -37.21% | -58.9% |
| Net Income (Continuing) | -10.58M | -12.69M | -16.39M | -14.73M | -33.15M | -42.35M | -29.82M | -39.83M | -54.65M | -52.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -441.47▲ 0% | -72.29▲ 83.6% | -39.15▲ 45.8% | -5.39▲ 86.2% | -4.05▲ 24.9% | -3.95▲ 2.5% | -1.50▲ 62.0% | -1.24▲ 17.3% | -1.25▼ 0.8% | -1.51▲ 0% |
| EPS Growth % | 70.07% | 83.63% | 45.84% | 86.23% | 24.86% | 2.47% | 62.03% | 17.33% | -0.81% | -22.12% |
| EPS (Basic) | -441.47 | -72.29 | -39.15 | -5.39 | -4.05 | -3.95 | -1.50 | -1.24 | -1.25 | - |
| Diluted Shares Outstanding | 23.97K | 175.51K | 412.32K | 2.72M | 8.12M | 10.59M | 19.83M | 32.07M | 43.59M | 34.69M |
| Basic Shares Outstanding | 23.97K | 175.51K | 412.32K | 2.72M | 8.12M | 10.59M | 19.83M | 32.07M | 43.59M | 34.69M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ACHV Balance Sheet
Achieve Life Sciences, Inc. (ACHV) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.91M | 15.54M | 17.33M | 36.98M | 44.59M | 27.33M | 16.98M | 36.47M | 39.89M | 50.05M |
| Cash & Short-Term Investments | 5.28M | 14.65M | 16.66M | 35.85M | 43.02M | 24.72M | 15.55M | 34.34M | 36.4M | 48.11M |
| Cash Only | 5.28M | 9.52M | 16.66M | 35.85M | 43.02M | 24.72M | 15.55M | 12.73M | 20.93M | 31.93M |
| Short-Term Investments | 0 | 5.09M | 0 | 0 | 0 | 0 | 0 | 21.61M | 15.47M | 16.18M |
| Accounts Receivable | 9K | 7K | 8K | 0 | 153K | 105K | 111K | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 222K | -50K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 287.34 | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 222K | 0 | -8K | 0 | 0 | 2.5M | 1.32M | 2.13M | 3.48M | 1.94M |
| Total Non-Current Assets | 3.98M | 3.55M | 3.74M | 3.32M | 2.92M | 2.64M | 2.39M | 2.17M | 1.9M | 1.98M |
| Property, Plant & Equipment | 59K | 35K | 386K | 146K | 64K | 123K | 79K | 119K | 64K | 79K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M |
| Intangible Assets | 2.53M | 2.31M | 2.09M | 1.86M | 1.64M | 1.42M | 1.2M | 974K | 0 | 807K |
| Long-Term Investments | 50K | 50K | 0 | 0 | 0 | 0 | 50K | 0 | 0 | 20K |
| Other Non-Current Assets | 359K | 168K | 237K | 279K | 183K | 66K | 29K | 39K | 803K | 426K |
| Total Assets | 9.89M▲ 0% | 19.08M▲ 92.9% | 21.08M▲ 10.4% | 40.3M▲ 91.2% | 47.52M▲ 17.9% | 29.97M▼ 36.9% | 19.37M▼ 35.4% | 38.63M▲ 99.4% | 41.79M▲ 8.2% | 52.04M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -63.99% | 92.92% | 10.45% | 91.19% | 17.91% | -36.92% | -35.37% | 99.44% | 8.17% | 38.07% |
| Total Current Liabilities | 2.01M | 3.27M | 2.87M | 2.94M | 4.55M | 21.6M | 20.81M | 6.68M | 9.08M | 9.73M |
| Accounts Payable | 213K | 144K | 859K | 332K | 841K | 1.66M | 618K | 1.95M | 859K | 1.94M |
| Days Payables Outstanding | 275.69 | 186.38 | 1.23K | 475.22 | - | - | - | 3.11K | - | 11.43K |
| Short-Term Debt | 27K | 11K | 0 | 0 | 0 | 16.07M | 16.66M | 0 | 3.77M | 1.26M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.29M | 1.94M | 1.12M | 1.47M | 1.94M | 1.68M | 2.84M | 3.03M | 5.32M | 4.09M |
| Current Ratio | 2.93x | 4.75x | 6.04x | 12.60x | 9.80x | 1.27x | 0.82x | 5.46x | 4.39x | 4.39x |
| Quick Ratio | 2.82x | 4.77x | 6.04x | 12.60x | 9.80x | 1.27x | 0.82x | 5.46x | 4.39x | 4.39x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 240K | 12K | 159K | 77K | 14.92M | 69K | 6K | 11.05M | 11.19M | 8.7M |
| Long-Term Debt | 0 | 12K | 0 | 0 | 14.92M | 0 | 0 | 9.84M | 11.19M | 8.67M |
| Capital Lease Obligations | 0 | 12K | 159K | 77K | 4K | 69K | 6K | 66K | 0 | 176K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | -12K | 0 | 0 | 0 | 0 | 0 | 1.15M | 0 | 2.39M |
| Total Liabilities | 2.01M | 3.28M | 3.03M | 3.01M | 19.47M | 21.67M | 20.82M | 17.73M | 20.27M | 18.43M |
| Total Debt | 27K | 23K | 362K | 169K | 14.99M | 16.2M | 16.73M | 9.96M | 14.96M | 9.96M |
| Net Debt | -5.26M | -9.49M | -16.3M | -35.68M | -28.03M | -8.52M | 1.19M | -2.77M | -5.97M | -21.97M |
| Debt / Equity | 0.00x | 0.00x | 0.02x | 0.00x | 0.53x | 1.95x | - | 0.48x | 0.70x | 0.70x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.19x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.42x |
| Interest Coverage | - | - | - | - | - | -22.81x | -9.55x | -17.92x | - | -67.43x |
| Total Equity | 7.88M▲ 0% | 15.8M▲ 100.6% | 18.05M▲ 14.2% | 37.29M▲ 106.6% | 28.04M▼ 24.8% | 8.3M▼ 70.4% | -1.45M▼ 117.4% | 20.9M▲ 1543.3% | 21.52M▲ 3.0% | 33.62M▲ 0% |
| Equity Growth % | -58.46% | 100.56% | 14.23% | 106.57% | -24.79% | -70.39% | -117.44% | 1543.3% | 2.96% | 1469.76% |
| Book Value per Share | 328.68 | 90.03 | 43.78 | 13.71 | 3.45 | 0.78 | -0.07 | 0.65 | 0.49 | 0.97 |
| Total Shareholders' Equity | 7.88M | 15.8M | 18.05M | 37.29M | 28.04M | 8.3M | -1.45M | 20.9M | 21.52M | 33.62M |
| Common Stock | 12K | 18K | 41K | 76K | 79K | 87K | 90K | 103K | 121K | 121K |
| Retained Earnings | -12.69M | -25.38M | -45.7M | -60.43M | -93.59M | -135.94M | -165.75M | -205.58M | -260.23M | -245.56M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 5K | 4K | 4K | 4K | 4K | 4K | 4K | 31K | 10K | 9K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACHV Cash Flow Statement
Achieve Life Sciences, Inc. (ACHV) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.11M | -10.62M | -15.22M | -13.47M | -29.44M | -37.57M | -24.48M | -29.77M | -49.47M | -49.47M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 69.32% | -16.65% | -43.24% | 11.45% | -118.49% | -27.61% | 34.84% | -21.61% | -66.16% | -313.78% |
| Net Income | -10.58M | -12.69M | -16.39M | -14.73M | -33.15M | -42.35M | -29.82M | -39.83M | -54.65M | -52.35M |
| Depreciation & Amortization | 282K | 282K | 254K | 255K | 250K | 236K | 228K | 229K | 228K | 229K |
| Stock-Based Compensation | 348K | 854K | 1.2M | 1.29M | 2.19M | 3.27M | 3.44M | 5.33M | 8.76M | 8.7M |
| Deferred Taxes | -3.05M | 0 | 0 | -2.32M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 6.99M | 1.49M | -3K | 2.32M | 41K | 1.2M | 2.45M | 2.09M | -3.81M | 799K |
| Working Capital Changes | -3.09M | 928K | -273K | -285K | 1.23M | 79K | -778K | 2.41M | 0 | 1.94M |
| Change in Receivables | -9K | 2K | -1K | 0 | -153K | 48K | 0 | 111K | 0 | 0 |
| Change in Inventory | -3.66M | 285K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 118K | -69K | 715K | -527K | 509K | 799K | -1.04M | 1.33M | -1.09M | 932K |
| Cash from Investing | 12.65M | -5.13M | 5.04M | -17K | 0 | 0 | -21K | -21.58M | 6.11M | 17.12M |
| Capital Expenditures | 0 | -46K | -53K | -17K | 0 | 0 | -21K | 0 | -3K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 12.65M | 10K | -5.09K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 12.65M | 10K | 5.09K | 0 | 0 | 0 | 0 | 0 | 3K | 0 |
| Cash from Financing | 2M | 19.76M | 17.32M | 32.68M | 36.61M | 19.32M | 15.28M | 48.53M | 51.53M | 45.95M |
| Debt Issued (Net) | 64K | 0 | 0 | 0 | 14.93M | 0 | 0 | -8.29M | 0 | 0 |
| Equity Issued (Net) | 1.94M | 18.43M | 13.13M | 29.5M | 21.34M | 19.21M | 15.27M | 56.08M | 0 | -10.81M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -30K | 0 | 0 | 0 |
| Other Financing | -5K | 1.32M | 4.2M | 3.18M | 338K | 103K | 7K | 746K | 51.53M | 56.76M |
| Net Change in Cash | 5.54M▲ 0% | 4.01M▼ 27.6% | 7.15M▲ 78.3% | 19.19M▲ 168.4% | 7.17M▼ 62.6% | -18.25M▼ 354.6% | -9.22M▲ 49.5% | -2.82M▲ 69.4% | 8.18M▲ 389.6% | 22.39M▲ 0% |
| Free Cash Flow | -9.11M▲ 0% | -10.67M▼ 17.2% | -15.27M▼ 43.1% | -13.49M▲ 11.6% | -29.44M▼ 118.2% | -37.57M▼ 27.6% | -24.5M▲ 34.8% | -29.77M▼ 21.5% | -49.47M▼ 66.2% | -40.68M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 69.37% | -17.15% | -43.12% | 11.64% | -118.22% | -27.61% | 34.79% | -21.51% | -66.17% | -63.03% |
| FCF per Share | -379.90 | -60.79 | -37.03 | -4.96 | -3.63 | -3.55 | -1.24 | -0.93 | -1.13 | -1.13 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.84x | 0.93x | 0.92x | 0.89x | 0.89x | 0.82x | 0.75x | 0.91x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACHV Key Ratios
Achieve Life Sciences, Inc. (ACHV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -78.85% | -107.15% | -96.86% | -52.99% | -101.49% | -233.04% | -869.88% | -409.51% | -257.67% | -196.68% |
| Return on Invested Capital (ROIC) | -153.97% | -215.18% | -307.67% | -660.45% | -3073.75% | - | - | -328.11% | - | -427.33% |
| Debt / Equity | 0.00x | 0.00x | 0.02x | 0.00x | 0.53x | 1.95x | - | 0.48x | 0.70x | 0.70x |
| Interest Coverage | - | - | - | - | - | -22.81x | -9.55x | -17.92x | - | -67.43x |
| FCF Conversion | 0.86x | 0.84x | 0.93x | 0.92x | 0.89x | 0.89x | 0.82x | 0.75x | 0.91x | 0.78x |
| Revenue Growth | -100% | - | - | - | - | - | - | - | - | - |
ACHV SEC Filings & Documents
Achieve Life Sciences, Inc. (ACHV) SEC filings — annual & quarterly reports (10-K, 10-Q)
ACHV Frequently Asked Questions
Achieve Life Sciences, Inc. (ACHV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Achieve Life Sciences, Inc. (ACHV) grew revenue by 0.0% over the past year. Growth has been modest.
Achieve Life Sciences, Inc. (ACHV) reported a net loss of $52.3M for fiscal year 2025.
Dividend & Returns
Achieve Life Sciences, Inc. (ACHV) has a return on equity (ROE) of -257.7%. Negative ROE indicates the company is unprofitable.
Achieve Life Sciences, Inc. (ACHV) had negative free cash flow of $40.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More ACHV
Achieve Life Sciences, Inc. (ACHV) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates